TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04105647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle-integrated exercise
Description: The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy living information
Description: The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
Study: NCT01959074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: aceclofenac 100mg on demand
Study: NCT04054960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa tablet
Description: We will give 3 tablets of Levodopa-Carbidopa (100/25).
Study: NCT02716727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquasil Ultra Cordless, Dentsply
Description: Cordless gingival displacement procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrapak, Ultradent cord
Description: Cordless gingival displacement procedure
Study: NCT04059224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg once a day by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg once a day by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
Study: NCT03167723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest tube placement
Description: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest tube placement
Description: Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
Study: NCT03810755

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Supervised physical activity
Description: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Supervised physical activity
Description: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
Study: NCT03046407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retinal pigment epithelium transplantation
Description: Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
Study: NCT02414438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FirstStepDX PLUS and NextStepDX PLUS Webinar
Description: A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FirstStepDX PLUS and NextStepDX PLUS Webinar
Description: A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FirstStepDX PLUS and NextStepDX PLUS Test Results
Description: Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
Study: NCT03021109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of inferior vena cava diameters with ultrasound
Description: The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
Study: NCT02908035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temsirolimus
Description: After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
Study: NCT04505137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMA301 Injection
Description: GMA301 Injection administered as a single dose of 1500 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMA301 Placebo Injection
Description: GMA301 Injection without GMA301 administered as a single intravenous dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMA301 Placebo Injection
Description: GMA301 Injection without GMA301 administered as a single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMA301 Injection
Description: GMA301 Injection administered as a single dose of 2000 mg
Study: NCT00989820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: 30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
Study: NCT04009512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Thoracoabdominal Stent Graft System
Description: This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Thoracoabdominal Stent Graft System
Description: This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
Study: NCT01672112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oral Oxycodone 5mg 6hrly/prn

Intervention type: DRUG
Group type: OTHER
Intervention: Codeine
Description: Oral Codeine 60mg 6hrly/prn
Study: NCT03205891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: 1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK228
Description: Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose Monitor
Description: Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
Study: NCT02540759

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buglossoides oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buglossoides oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Buglossoides oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Sunflower Oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Sunflower Oil
Study: NCT04322955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 2 x 20 mg capsules taken orally daily
Study: NCT02540759

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Sunflower Oil
Study: NCT01717586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
Study: NCT02189980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy blend
Description: A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of effectiveness of the essential oil blend
Description: Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Duration of effectiveness of the essential oil blend
Description: Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant comfort using the nasal clip delivery system
Description: Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Participant comfort using the nasal clip delivery system
Description: Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
Study: NCT04322955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg IV on first day of each 28-day cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy
Description: Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.
Study: NCT02532569

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Japanese encephalitis vaccine
Description: Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
Study: NCT02693691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Description: Pulmonary Artery Pressure Monitoring
Study: NCT04413331

Intervention type: OTHER
Intervention: Data collection
Description: Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse

Intervention type: OTHER
Intervention: Data collection
Description: Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse

Intervention type: OTHER
Intervention: Biological samples and data collection
Description: Biological samples at M0, M6, M12, M24 and at each relapse until M60

Intervention type: OTHER
Intervention: Biological samples and data collection
Description: Biological samples at M0, M6, M12, M24 and at each relapse until M60
Study: NCT02175316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation
Description: Enhanced External Counterpulsation
Study: NCT00237783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dialysate sodium (140 mmol/L)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: individualized dialysate sodium
Description: individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
Study: NCT02760524

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NET Intervention
Description: Neuro-emotional Technique

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET Intervention
Description: Neuro-emotional Technique
Study: NCT02932306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121 Lotion
Description: IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-121 Vehicle Lotion
Description: IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Study: NCT01306851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin glue
Description: In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
Study: NCT03371251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS161721
Description: SC administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration
Study: NCT01593514

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Description: The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Description: The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
Study: NCT04206631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline Capsule
Description: Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comedone extraction
Description: Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
Study: NCT00288886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contracting, Prompting and Reinforcement arm
Description: Contracting, prompting and reinforcement of continuing care and abstinence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Routine residential treatment and orientation to continuing care.
Study: NCT04377958

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum biomarker testing
Description: Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
Study: NCT01593514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Description: The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Description: To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
Study: NCT04005391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offer of Participant's Choice of Contraception Method
Description: Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
Study: NCT01255839

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Balloon
Description: The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minprostin
Description: The prostaglandin 2 minprostin (3mg) was applied vaginally
Study: NCT01959074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: aceclofenac 100mg on demand
Study: NCT03371251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration
Study: NCT00739960

Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept
Description: 10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
Study: NCT05587634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer Health Coaching
Description: Intervention arm: weekly sessions (\~30 min each session) of physical activity counseling with an assigned peer health coach over the course of 12 weeks. The focus of the initial 2 calls is on rapport development and trust building with a focus around PA with discussion of physical activity goals and motives, where possible. The remainder of the call sessions follow a standardized format of a 30-minute call to 1) review the previous week, 2) integrate motivational strategies, and 3) develop action and support plans for the next week. The final call format includes a summary and evaluation of the intervention, discussion of short- and long-term goals, and relapse prevention strategies. Sessions guided by a call tracking form.~These participants receive an adaptive physical activity local guide including information on local adaptive sports opportunities, which the control group also receives.
Study: NCT01927887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanoparticle MRI
Description: Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
Study: NCT02726334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC101 Solution for Infusion
Description: Administration: Administered via IV infusion once a week over 60 minutes (1 hour).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNC101 in combination with FOLFIRI
Description: BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days.
Study: NCT02443805

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 300 IR
Description: 300 IR tablet of HDM Allergen Extracts

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT03656666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: Apremilast oral tablets
Study: NCT01593514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide (subcutaneously)-conjugate
Description: The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
Study: NCT03379389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine + Methylthioninium
Description: Methenamine + Methylthioninium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methenamine + Methylthioninium + Acriflavine + Atropa belladona
Description: Methenamine + Methylthioninium + Acriflavine + Atropa belladona

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Antibiotics based on individual subjects urine culture / antibiogram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Antibiotics based on individual subjects urine culture / antibiogram
Study: NCT04638335

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: blood test for Anti-HAV antibodies

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: blood test for Anti-HAV antibodies